logo
logo
JANX stock ticker logo

Janux Therapeutics, Inc.

NASDAQ•JANX
CEO: Dr. David Alan Campbell Ph.D.
Sector: Healthcare
Industry: Biotechnology
Listing Date: 2021-06-11
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
Contact Information
10955 Vista Sorrento Parkway, Suite 200, San Diego, CA, 92130, United States
858-751-4493
www.januxrx.com
Market Cap
$844.34M
P/E (TTM)
-7.6
17.5
Dividend Yield
--
52W High
$35.34
52W Low
$12.12
52W Range
8%
Rank53Top 76.1%
2.8
F-Score
Modified Piotroski Analysis
Based on 6-year fundamentals
Weak • 2.8 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2020-2025

Financial Dashboard

Q4 2025 Data

Revenue

$7.88M+0.00%
4-Quarter Trend

EPS

-$0.51+0.00%
4-Quarter Trend

FCF

$54.63M+0.00%
4-Quarter Trend

2025 Annual Earnings Highlights

Key Highlights

Lead Candidates Advance Trials JANX007 (PSMA TRACTr) and JANX008 (EGFR TRACTr) advanced into Phase 1b and Phase 1a expansion cohorts, respectively.
Strong Liquidity Position Cash, equivalents, and short-term investments totaled $967.4M as of December 31, 2025, supporting operations and R&D.
New BMS Collaboration Agreement Exclusive license agreement signed with BMS in January 2026, including $15.0M upfront payment and significant milestone potential.
R&D Spending Rises Research and development expenses increased $57.5M to $125.9M in 2025, driven by preclinical and clinical program costs.

Risk Factors

Need Substantial Future Capital Existing cash insufficient to fund product candidates through regulatory approval, requiring significant future equity or debt financing.
Early Stage Development Risk All programs besides JANX007/JANX008 are preclinical; clinical trial results are uncertain and not predictive of future success.
Intense Competitive Landscape Face significant competition from large pharma targeting PSMA/EGFR, potentially limiting market entry speed and commercial viability.
Patent Protection Uncertainty Proprietary position relies on patents; scope uncertainty, potential invalidation, or competitor infringement risk could impair market position.

Outlook

Advance Lead TRACTr Development Focus on advancing JANX007 and JANX008 through clinical development, refining dosing and patient selection strategies.
Expand TRACTr Product Candidates Leverage modular platform to progress discovery of new TRACTr candidates against various clinically validated targets.
Expand Beyond TCE Therapeutics Develop internal pipeline into logical classes beyond TCEs, utilizing ARM platform for autoimmune indications like CD19-ARM.

Peer Comparison

Revenue (TTM)

HRMY stock ticker logoHRMY
$868.45M
+21.5%
MNKD stock ticker logoMNKD
$348.97M
+22.2%
RCUS stock ticker logoRCUS
$247.00M
-4.3%

Gross Margin (Latest Quarter)

CLDX stock ticker logoCLDX
100.0%
+0.0pp
ABCL stock ticker logoABCL
100.0%
+588.5pp
NUVB stock ticker logoNUVB
99.0%
+182.9pp

Key Metrics

Symbol
Market Cap
P/E (TTM)
ROE (TTM)
Debt to Assets
EWTX$3.19B-18.3-32.0%0.7%
VERA$2.86B-8.6-59.7%10.5%
VRDN$2.44B-7.1-58.4%5.6%

Long-Term Trends

Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4Q Revenue CAGR
N/M
Revenue Volatile
4Q Net Income CAGR
N/M
Profitability Shift
Cash Flow Stability
25%
Cash Flow Needs Attention

Deep Research

Next earnings:May 6, 2026
|
EPS:-
|
Revenue:-
Financials
Earnings Calls
Reports
News
Income Statement
Balance Sheet
Cash Flow Statement
Ratios
% Chg.
Income Statement
LTM
No Data